Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671421 | 0.90 | SMN1; SMN2 (0.38) | HPGDBDKRB1SMN1; SMN2RIPK1TSHR | |
| SCHEMBL15170281 | 0.87 | RIPK1 (0.41) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL15170299 | 0.86 | RIPK1 (0.41) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL1671356 | 0.84 | EPHX2 (0.38) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL15169817 | 0.81 | PTGES (0.45) | MEN1KMT2APTGES | |
| SCHEMBL1671459 | 0.76 | CA12 (0.47) | ALDH1A1HPGDSMN1; SMN2TSHRTP53 | |
| SCHEMBL1671306 | 0.76 | CYP4F2 (0.56) | ALDH1A1HPGDSMN1; SMN2TSHRLMNA | |
| SCHEMBL1671550 | 0.76 | EPHX2 (0.39) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL1671130 | 0.73 | EPHX2 (0.40) | ALDH1A1RIPK1HDAC6KDM4EPTGES | |
| SCHEMBL15540907 | 0.72 | CA1 (0.39) | RIPK1HDAC6PTGESCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2491007-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | PDK1 2566/4885PDK2 2075/4885PDK3 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.